MIR34A and cancer: Taken together, myeloid Mir34a-deficient CACs show a prominent increase of cancer cells with enhanced inflammatory signaling, which display a partially mesenchymal signature and may therefore represent cancer cells with enhanced migratory and invasive capacities.